IP Verse

Nanostructured Aprepitant Compositions, Process For The Preparation Thereof And Pharmaceutical Compositions Containing Them - EP2582697

The patent EP2582697 was granted to Druggability Holdco Jersey on Sep 27, 2017. The application was originally filed on Jun 17, 2011 under application number EP11736150A. The patent is currently recorded with a legal status of "Revoked".

EP2582697

DRUGGABILITY HOLDCO JERSEY
Application Number
EP11736150A
Filing Date
Jun 17, 2011
Status
Revoked
Jul 10, 2020
Publication Date
Sep 27, 2017
External Links
Slate, Register, Google Patents

Patent Summary

Patent Family

Patent Family

Patent Oppositions

Patent oppositions filed by competitors challenge the validity of a granted patent. These oppositions are typically based on claims of prior art, lack of novelty, or non-obviousness. They are a key part of the process for determining a patent's strength and enforceability.

CompanyOpposition DateRepresentativeOpposition Status

Get instant alerts for new oppositions and patent status changes

ALKERMES PHARMA IRELANDJun 27, 2018POHLMANADMISSIBLE

Patent Citations (30) New

Patent citations refer to prior patents cited during different phases such as opposition or international search.

Citation PhasePublication Number
DESCRIPTIONUS2008214535
DESCRIPTIONUS5145684
DESCRIPTIONUS5534270
DESCRIPTIONUS5543133
DESCRIPTIONUS5665331
DESCRIPTIONUS5718388
DESCRIPTIONUS5719147
DESCRIPTIONUS5862999
DESCRIPTIONUS6048859
DESCRIPTIONUS6096742
DESCRIPTIONUS6235735
DESCRIPTIONWO2007016582
DESCRIPTIONWO2007088483
DESCRIPTIONWO2007112457
DESCRIPTIONWO2007147160
DESCRIPTIONWO2008044102
DESCRIPTIONWO2008104512
DESCRIPTIONWO2009001203
DESCRIPTIONWO2009108828
INTERNATIONAL-SEARCH-REPORTWO03049718
INTERNATIONAL-SEARCH-REPORTWO2007088483
INTERNATIONAL-SEARCH-REPORTWO2008104512
INTERNATIONAL-SEARCH-REPORTWO2009131930
INTERNATIONAL-SEARCH-REPORTWO2010092591
INTERNATIONAL-SEARCH-REPORTWO2010140132
OPPOSITIONEP1455756
OPPOSITIONUS2007104792
OPPOSITIONUS4826689
OPPOSITIONUS5145684
OPPOSITIONWO2009133418

Non-Patent Literature (NPL) Citations (15) New

NPL citations refer to non-patent references such as research papers, articles, or other publications cited during examination or opposition phases.

Citation PhaseReference Text
INTERNATIONAL-SEARCH-REPORT- SHONO Y ET AL, "Forecasting in vivo oral absorption and food effect of micronized and nanosized aprepitant formulations in humans", EUROPEAN JOURNAL OF PHARMACEUTICS AND BIOPHARMACEUTICS, ELSEVIER SCIENCE PUBLISHERS B.V., AMSTERDAM, NL, vol. 76, no. 1, ISSN 0939-6411, (20100601), pages 95 - 104, (20100601), XP027210087 [X] 1-8 * figure 8 *
INTERNATIONAL-SEARCH-REPORT- WU Y ET AL, "The role of biopharmaceutics in the development of a clinical nanoparticle formulation of MK-0869: a Beagle dog model predicts improved bioavailability and diminished food effect on absorption in human", INTERNATIONAL JOURNAL OF PHARMACEUTICS, ELSEVIER BV, NL, (20041105), vol. 285, no. 1-2, doi:10.1016/J.IJPHARM.2004.08.001, ISSN 0378-5173, pages 135 - 146, XP004602823 [X] 1-8 * paragraph [2.3.1] *
INTERNATIONAL-SEARCH-REPORT- IAN OLVER ET AL, "Nanomedicines in the treatment of emesis during chemotherapy: focus on aprepitant", INTERNATIONAL JOURNAL OF NANOMEDICINE, DOVE MEDICAL PRESS LTD, AUCKLAND, NZ, (20070501), vol. 2, no. 1, doi:10.2147/IJN.S, ISSN 1176-9114, pages 13 - 18, XP009152304 [I] 1-8 * the whole document *
OPPOSITION- CHEN et al., "Quantitative Analysis of Powder Mixtures by Raman Spectrometry: the influence of particle size and its correction", Analytical Chemistry, (20120000), vol. 84, no. 9, pages 4088 - 4094, XP055515615
OPPOSITION- C TIMPE, "Combining Science and technology to create advanced drug delivery systems", APV fOCUS Group Drug Delivery, International Association for Pharmaceutical Technology Newsletter, (20100000), pages 1 - 16, XP055515006
OPPOSITION- E. FALLON, Declaration
OPPOSITION- "Emend aprepitant capsul", FDA NDA 21-549, (20030300), pages 21 - 549, XP055515592
OPPOSITION- "Emend (fosaprepitant dimenglumine)", Emend (powder) FDA label NDA 22-023, (20080000), pages 1-17 - 2, 3, XP055515599
OPPOSITION- M. AULTON, Pharmaceutics: the science of dosage form design, (19880000), pages 277 - 278, ISBN 0-443-03643-8, XP055515040
OPPOSITION- MOSCHWITZER et al., "Chapter 5", MOSCHWITZER et al., THASSU D. ET AL., Nanoparticulate drug Delivery Systems, (20050629), pages 71 - 88, ISBN 0-8493-9073-7, XP055515020
OPPOSITION- "SOLUPLUS 005346234", EUIPO, (20180524), pages 1 - 3, XP055515609
OPPOSITION- MERISKO-LIVERSIDGE ET AL et al., Advanced Drug Delivery Reviews, (20110109), vol. 63, pages 427 - 440, XP028374102
OPPOSITION- ANGI ET AL et al., "Novel continuous flow technology for the development of a nanostructured Aprepitant formulation with improved pharmacokinetic properties", European Journal of Pharmaceutics & Biopharmaceutics, (20140000), vol. 86, pages 361 - 368, XP028845346
OPPOSITION- WU et al., "The role of biopharmaceutics in the development of a clinical nanoparticle formulation of MK-0869: a Beagle dog model predicts improved bioavailability and diminished food effect on absorption in human.", International Journal of Pharmaceutics, (20041105), vol. 285, pages 135 - 146, XP004602823
OPPOSITION- ALI et al., "Preparation of hydrocortisone nanosuspension through a bottom-up nanoprecipitation technique using microfluidic reactors.", International Journal of Pharmaceutics, (20090000), vol. 375, pages 107 - 113, XP026143342

Download Citation Report

Get a free citation report including examiner, opposition, and international search citations.

Get Citation Report

Dossier Documents

The dossier documents provide a comprehensive record of the patent’s prosecution history - including filings, correspondence, and decisions made by patent offices - and are crucial for understanding the patent’s legal journey and any challenges it may have faced during examination.

  • Date

    Description

  • Get instant alerts for new documents